A split-face study comparing the incidence of postinflammatory hyperpigmentation following a 532-nm Picosecond laser: broad-spectrum vs. broad-spectrum with iron oxide sunscreens

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230417004

Enrollment

Registered

2023-04-17

Start date

2023-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solar lentigines PIH Visible light Sunscreen

Interventions

Patients will receive broad-spectrum with iron oxide sunscreens to apply once daily on one side of the face after receiving picosecond laser treatment on solar lentigines.,Patients will receive broad-

Experimental Drug,Active Comparator Drug

broad-spectrum with iron oxide sunscreens,broad-spectrum without iron oxide sunscreens

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Asian with Fitzpatrick Skin type III-V 2. Was diagnosed by a physician as Solar lentigines 3. There are solar lentigines lesions on both sides of the face. The lesion size is greater than 6 mm.

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Patients with dermatitis, wounds, or skin infections on the face 3. Patients with a history of allergy to anesthetics that cannot use cold air during treatment instead. 4. Patients with a history of allergy to sunscreen or iron oxide allergy 5. Patients with other diseases related to pigmentation abnormalities, such as melasma, hori nevus, nevus of ota, freckles, etc., in the same area as solar lentigines 6. Patients with a history of herpes on the face or suffering from herpes on the face 7. Patients with mental disorders whom a psychiatrist has diagnosed. 8. Patients considered by the researcher to be unsafe if participating in the program 9. Patients who are not allowed to take pictures for treatment evaluation

Design outcomes

Primary

Measure	Time frame
Incidence of PIH 2 weeks, 4 weeks, 8 weeks, 12 weeks after treatment Clinical evaluation	—

Secondary

Measure	Time frame
Average melanin concentration Before treatment, 2 weeks, 4 weeks, 8 weeks, 12 weeks after treatment Antera 3D analysis,Melanin index Before treatment, 2 weeks, 4 weeks, 8 weeks, 12 weeks after treatment Mexameter MX 18	—

Countries

Thailand

Contacts

Public ContactThrit Hutachoke

Faculty of Medicine Siriraj Hospital, Mahidol University

maxover2@gmail.com0818032865

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026